Patients with COVID-19 pneumonia receiving standard of care as per Ministry of Health Protocol of Treatment plus placebo

patients with COVID-19 pneumonia receiving standard of care as per Ministry of Health Protocol of Treatment + Silymarin Oral 420mg/day in 3 divided doses

COVID-19

Viral Pneumonia Human Coronavirus

Silymarin Oral at a dose of 420 mg/day in 3 divided doses.

Silymarin

Placebo

Cairo University

Silymarin in COVID-19 Pneumonia

Trial of Silymarin in Adults With COVID-19 Pneumonia

Defined as the time from randomization to an improvement of two points (from the status of randomization) on seven category ordinal scale or live discharge from the hospital, whichever comes first.

Clinical status as assessed with the seven-category ordinal scale on days 7 and 14

number of days patient remained with positive RT-PCR SARS-CoV-2 swab

Any adverse events whether related to medication or not

Khaled Mohammed Korany Salem

Assistant Lecturer

Group 1 (Control): Includes 25 patients with COVID-19 pneumonia receiving standard of care as per Ministry of Health Protocol of Treatment + placebo Group 2 (Intervention): Includes 25 patients with COVID-19 pneumonia receiving standard of care as per Ministry of Health Protocol of Treatment + Silymarin Oral at a dose of 420 mg/day in 3 divided doses.

50 Caucasian never-treated hypertensive outpatients, 27 males and 23 women, age range 42-60 years (mean+SD=52+7), showing normal glucose tolerance but 1-h post load plasma glucose >155 mg/dl, during the OGTT.

Hypertension

After enrollment, all patients were encouraged to make lifestyle changes according with current guidelines, moreover it was also recommended to take silybin coniugated to vitamin E and phosphatidylcholine that shows higher intestinal absorption and bioavailability (Indena, IBI-Lorenzini spa Italy: Realsil®), as granules for oral solution at a dose of 3 g bid. Each subject was re-evaluated monthly performing a clinical examination to consider the opportunity of antihypertensive treatment. Finally, inflammatory, metabolic and hemodynamic parameters were assessed after 6 months of treatment. In particular, at the end of the follow-up period, a new OGTT was performed, to test the effects of silybin on glucose tolerance and IR status.

Silybin

Effects of Silybin in Hypertensive Patients

Metabolic and Vascular Effects of Silybin in Hypertensive Patients With High One-hour Post-load Plasma Glucose: a Single Arm Pilot Study

Fasting plasma glucose (mg/dL) will be measured after six months of treatment with silybin

2h post-load plasma glucose (mg/dL) will be determined after six months of treatment with silybin

Fasting insulin (mU/L) will be measured after six months of treatment with silybin

Total cholesterol (mg/dL) will be measured after six months of treatment with silybin

HDL-cholesterol (mg/dL) will be measured after six months of treatment with silybin

LDL-cholesterol (mg/dL) will be measured after six months of treatment with silybin

SBP (mmHg) will be measured after six months of treatment with silybin .

DBP (mmHg) will be measured after six months of treatment with silybin

PP will be measured after six months of treatment with silybin.

PWV (m/s) will be measured after six months of treatment with silybin

AI will be measured after six months of treatment with silybin

AP (mmHg) will be measured after six months of treatment with silybin

Measurement of serum hs-CRPhs-CRP (mg/dL) will be measured after six moths of treatment with silybin

Maria Perticone

Principal Investigator

University Magna Graecia

Pilot, single arm, interventional, longitudinal study

Hepatitis C

Intravenous Silibinin (iSIL)

Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich

THISTLE - The HIV-HCV Silibinin Trial

A Phase II, Multi-center, Open-label, Interventional Study to Evaluate the Safety of Intravenous Silibinin (iSIL) and Its Effect on the Hepatitis C Virus Load in Treatment-experienced HCV-HIV Co-infected Individuals With Advanced Liver Fibrosis in the Swiss HIV Cohort Study (SHCS)

The participants will be followed for the duration of study-drug administration and one day follow-up, which counts for 15days

University of Zurich

Patients who were unable or unwilling to use desferrioxamine or had stopped desferrioxamine treatment for at least 6 months, were received only silymarin.

In combined therapy group, patients continued desferrioxamine (Novartis Pharma AG, Switzerland) at the dose of 40 mg/Kg/day and Legalon® tablets (Madaus Pharma, Italy) was added to desferrioxamine regimen at the dose of 140 mg, taken orally, three times a day, 7 days a week.

Immune Abnormalities

Desferrioxamine (Novartis Pharma AG, Switzerland) at the dose of 40 mg/Kg/day and Legalon® tablets (Madaus Pharma, Italy)

Desferrioxamine, Legalon® (Silymarin)

Silymarin (Legalon)

Department of Immunology, School of Medicine, Shiraz University of Medical Sciences

Immunomodulatory Effects of Silymarin in Patients With Beta-Thalassemia Major

PHA-activated T Cell Proliferation in Cell Culture was studied by Brdu Incorporation ELISA-based Assay

The percentage of T cell, B cell, and NK cells were studied using flowcytometry

The concentrations of IL-2, IL-4, and IFN-gamma in supernatant of activated T cells were measured using ELISA assay.

Marjan Gharagozloo

Assistant professor

Shiraz University of Medical Sciences

Advanced Hepatocellular Carcinoma

4 dose levels of siliphos: 2, 4, 8, and 12 grams daily in three divided doses. This study will follow a standard sequential Phase I dose escalation design.

Columbia University Medical Center

Siliphos in Advanced Hepatocellular Carcinoma

Phase I Trial of Siliphos in Patients With Advanced Hepatocellular Carcinoma

Fasting morning blood samples collected at baseline, weeks 1, 3, 6, 9, and 12

Questionnaire administered at baseline, weeks 1, 6, and 12

Fasting morning blood samples collected at baseline, weeks 1, 3, 6, and 12

Fasting blood samples collected at baseline, weeks 1, 3, 6, 9, and 12 for AFP concentrations.
MRI of abdomen/pelvis & CT of chest at baseline and week 12

Abby Siegel

Assistant Professor of Clinical Medicine, Oncology

Lotte & John Hecht Memorial Foundation

1 tablet (equivalent to 140 mg silymarin) 3 times a day for 3 weeks

200mg vit E twice a day + 1 tablet of Milk Thistle extract 3 times a day for 3 weeks

Hemodialysis

End Stage Renal Disease

1 tablet equivalent to 140 mg of silymarin, 3 times daily for 3 weeks

Milk Thistle extract

vit E

200 mg vit E twice daily + 1 tablet of Milk Thistle 3 times daily for 3 weeks

lamyropsis microcephala/põletikuvastane

Silymarin in COVID-19 Pneumonia

Effects of Silybin in Hypertensive Patients

THISTLE - The HIV-HCV Silibinin Trial

Immunomodulatory Effects of Silymarin in Patients With Beta-Thalassemia Major

Siliphos in Advanced Hepatocellular Carcinoma

Comparative Effects of Milk Thistle Extract With Vitamin-E in Hemodialysis Patients

Kõige täiuslikum ravimtaimede andmebaas, mida toetab teadus